H. Lanz's Profile

Role	Title	Level	Year	L/R
🐜	Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects 24 auth. S. Boekholdt, F. Sacks, J. Jukema, J. Shepherd, D. Freeman, A. McMahon, F. Cambien, V. Nicaud, G. J. de Grooth, P. Talmud, ... S. Humphries, G. Miller, G. Eiriksdottir, V. Gudnason, H. Kauma, S. Kakko, M. Savolainen, M. Arca, A. Montali, S. Liu, H. Lanz, A. Zwinderman, J. Kuivenhoven, J. Kastelein	8	2005	8 🐜
🐜	Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate 13 auth. H. Zahir, K. Brown, A. Vandell, Madhuri Desai, J. Maa, V. Dishy, Barbara Lomeli, A. Feussner, Wenqin Feng, Ling He, ... M. Grosso, H. Lanz, E. Antman	7	2015	7 🐜
🐜	Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. 36 auth. N. Van Mieghem, M. Unverdorben, C. Hengstenberg, H. Möllmann, R. Mehran, D. Lopez-Otero, L. Nombela‐Franco, R. Moreno, P. Nordbeck, H. Thiele, I. Lang, J. Zamorano, F. Shawl, M. Yamamoto, Y. Watanabe, ... K. Hayashida, R. Hambrecht, F. Meincke, P. Vranckx, James Jin, E. Boersma, J. Rodés‐Cabau, P. Ohlmann, P. Capranzano, Hyo‐Soo Kim, T. Pilgrim, Richard Anderson, U. Baber, A. Duggal, P. Laeis, H. Lanz, Cathy Chen, M. Valgimigli, R. Veltkamp, S. Saito, G. Dangas	7	2021	7 🐜
🐜	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. 14 auth. G. Raskob, N. van Es, A. Segers, P. Angchaisuksiri, D. Oh, Z. Boda, R. Lyons, K. Meijer, I. Gudz, J. Weitz, ... George Zhang, H. Lanz, M. Mercuri, H. Büller	7	2016	7 🐜
🐜	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48) 12 auth. M. Link, R. Giugliano, C. Ruff, B. Scirica, H. Huikuri, A. Oto, ... A. E. Crompton, S. Murphy, H. Lanz, M. Mercuri, E. Antman, E. Braunwald	7	2017	7 🐜
🐜	Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban 11 auth. J. Ansell, S. Bakhru, B. Laulicht, S. Steiner, M. Grosso, K. Brown, ... V. Dishy, H. Lanz, M. Mercuri, R. Noveck, J. Costin	7	2016	7 🐜
🐜	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48 10 auth. D. Berg, C. Ruff, P. Jarolím, R. Giugliano, F. Nordio, H. Lanz, ... M. Mercuri, E. Antman, E. Braunwald, D. Morrow	6	2019	6 🐜
🐜	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. 10 auth. G. Boriani, C. Ruff, J. Kuder, M. Shi, H. Lanz, H. Rutman, ... M. Mercuri, E. Antman, E. Braunwald, R. Giugliano	6	2019	6 🐜
🐜	Evaluation of the safety and efficacy of an edoxaban‐based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST‐AF PCI trial 10 auth. P. Vranckx, T. Lewalter, M. Valgimigli, J. Tijssen, P. Reimitz, L. Eckardt, ... H. Lanz, W. Zierhut, R. Smolnik, A. Goette	6	2018	6 🐜
🐜	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial 13 auth. A. Eisen, C. Ruff, E. Braunwald, F. Nordio, R. Corbalán, A. Dalby, M. Dorobanțu, M. Mercuri, H. Lanz, H. Rutman, ... S. Wiviott, E. Antman, R. Giugliano	6	2016	6 🐜